Brokerages Set Aclaris Therapeutics Inc (ACRS) Price Target at $40.00

Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) have received a consensus rating of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $47.25.

Several analysts have weighed in on the stock. Zacks Investment Research cut shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. BidaskClub upgraded shares of Aclaris Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $50.00 price objective on shares of Aclaris Therapeutics in a research note on Tuesday, November 6th. Finally, JMP Securities dropped their price objective on shares of Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating for the company in a research note on Tuesday, October 16th.

Shares of Aclaris Therapeutics stock opened at $8.26 on Wednesday. Aclaris Therapeutics has a twelve month low of $8.00 and a twelve month high of $26.25. The stock has a market capitalization of $351.64 million, a price-to-earnings ratio of -3.30 and a beta of 1.40.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.06) earnings per share for the quarter, topping the consensus estimate of ($1.25) by $0.19. Aclaris Therapeutics had a negative net margin of 1,578.24% and a negative return on equity of 63.74%. The business had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $1.58 million. Equities analysts expect that Aclaris Therapeutics will post -4 earnings per share for the current fiscal year.

In other news, Director Stephen A. Tullman bought 7,100 shares of the company’s stock in a transaction dated Thursday, October 4th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $99,400.00. Following the transaction, the director now owns 177,457 shares of the company’s stock, valued at $2,484,398. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Anand Mehra bought 372,093 shares of the company’s stock in a transaction dated Monday, October 22nd. The stock was purchased at an average price of $10.75 per share, with a total value of $3,999,999.75. The disclosure for this purchase can be found here. 17.00% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of ACRS. FMR LLC raised its position in shares of Aclaris Therapeutics by 31.1% in the 2nd quarter. FMR LLC now owns 3,355,785 shares of the biotechnology company’s stock valued at $67,015,000 after buying an additional 796,805 shares in the last quarter. Man Group plc raised its position in shares of Aclaris Therapeutics by 396.1% in the 3rd quarter. Man Group plc now owns 402,624 shares of the biotechnology company’s stock valued at $5,846,000 after buying an additional 321,458 shares in the last quarter. Morgan Stanley raised its position in shares of Aclaris Therapeutics by 481.8% in the 3rd quarter. Morgan Stanley now owns 383,818 shares of the biotechnology company’s stock valued at $5,573,000 after buying an additional 317,847 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Aclaris Therapeutics by 1,417.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 238,553 shares of the biotechnology company’s stock valued at $3,464,000 after buying an additional 222,836 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of Aclaris Therapeutics by 8.9% in the 3rd quarter. BlackRock Inc. now owns 2,517,412 shares of the biotechnology company’s stock valued at $36,551,000 after buying an additional 205,771 shares in the last quarter. Institutional investors own 72.36% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Featured Article: Average Daily Trade Volume – What You Need to Know

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply